Dipyridamole (Persantine) 是具有口服活性的磷酸二酯酶 (PDE) 抑制剂,能阻断红细胞和血管内皮细胞对腺苷的吸收和代谢。Dipyridamol 也是一种用于脑卒中二级预防的抗血小板剂。Dipyridamol 可诱导肿瘤细胞特异性凋亡。
生物活性 | Dipyridamole is an orally activephosphodiesterase(PDE) inhibitor. Dipyridamole also is anantiplatelet agentused in secondary prophylaxis against stroke. Dipyridamole can inducecancercell-specificapoptosis[1][2][3]. |
IC50& Target | |
体外研究 (In Vitro) | Dipyridamole (5 μM; 15 min) results in a 2.5-fold increase in intracellular cAMP levels in OCI-AML-3 cells[2].Dipyridamole (5 μM; 48 h) with the statin combination induces apoptosis in primary AML cells[2].Dipyridamole (5 μM; 48 h) possesse cAMP/PKA-independent activity against statininduced SREBP2 activation[2].
Apoptosis Analysis[2] Cell Line: | AML (OCI-AML-2, OCI-AML-3) cell line | Concentration: | 5 μM | Incubation Time: | 48 h | Result: | Induced apoptosis with the combination of fluvastatin and dipyridamole, cilostazol, forskolin, or dbcAMP in OCI-AML-2 and OCI-AML-3 cells. |
RT-PCR[2] Cell Line: | LP1 cell line | Concentration: | 5 μM | Incubation Time: | 16 h | Result: | Increased the sensibility of cancer cells to statin-induced apoptosis. |
|
体内研究 (In Vivo) | Dipyridamole (10 mg/kg; p.o. once daily for 18 d) mitigates tumor growth, ameliorated concurrent alterations in blood circulation and tumor tissues, and platelet infiltration in tumor tissues[3].
Animal Model: | C57BL/6-LLC tumor-bearing mice models[3] | Dosage: | 10 mg/kg | Administration: | Oral gavage; 10 mg/kg; once daily for 18 days | Result: | Mitigated tumor growth in tumor-bearing mice. |
|
Clinical Trial | |
分子量 | |
性状 | |
Formula | |
CAS 号 | |
中文名称 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | 4°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) |
溶解性数据 | In Vitro: DMSO : ≥ 50 mg/mL(99.08 mM) H2O : 0.67 mg/mL(1.33 mM;Need ultrasonic) *"≥" means soluble, but saturation unknown. 配制储备液 1 mM | 1.9816 mL | 9.9082 mL | 19.8165 mL | 5 mM | 0.3963 mL | 1.9816 mL | 3.9633 mL | 10 mM | 0.1982 mL | 0.9908 mL | 1.9816 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month (protect from light)。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.5 mg/mL (4.95 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (4.95 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.5 mg/mL (4.95 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (4.95 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 3. 请依序添加每种溶剂: 10% DMSO 90%corn oil Solubility: ≥ 2.5 mg/mL (4.95 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (4.95 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|